IGMSライブシグナル | Getagraph.comで利益を最大化

買う 107871 min ago

@ $15.41

発行日: 15 2月 2024 @ 03:56

リターン: -33.61%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -4.82 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases...

Stats
本日の出来高	307 136
平均出来高	282 635
時価総額	603.03M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.840 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.17
ATR14	$0.0640 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Harler Mary Beth	Sell	0	Common Stock
2024-04-14	Harler Mary Beth	Sell	200 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	75 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	52 500	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	92 500	Stock Option (right to buy)

INSIDER POWER
56.95
Last 99 transactions
Buy: 2 356 293 \| Sell: 614 616

ボリューム相関

長: 0.09 (neutral)

短: -0.97 (very strong negative)

Signal:(45.236) Neutral

IGM Biosciences Inc 相関

10 最も正の相関
LWAC	0.811

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

IGM Biosciences Inc 相関 - 通貨/商品

0.76
( moderate )

0.79
( moderate )

0.00
( neutral )

0.61
( weak )

0.03
( neutral )

-0.29
( neutral )

IGM Biosciences Inc 財務諸表

Annual	2023
収益:	$2.13M
総利益:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2023
収益:	$2.13M
総利益:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2022
収益:	$1.07M
総利益:	$-9.53M (-891.77 %)
EPS:	$-5.16

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.37

Financial Reports:

No articles found.

IGM Biosciences Inc

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.